GR1007084B - 1,4-benzoxazine derivatives - Google Patents
1,4-benzoxazine derivativesInfo
- Publication number
- GR1007084B GR1007084B GR20080100530A GR20080100530A GR1007084B GR 1007084 B GR1007084 B GR 1007084B GR 20080100530 A GR20080100530 A GR 20080100530A GR 20080100530 A GR20080100530 A GR 20080100530A GR 1007084 B GR1007084 B GR 1007084B
- Authority
- GR
- Greece
- Prior art keywords
- subject
- pharmaceutically acceptable
- compound
- administering
- ester
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
excitotoxic brain injury, metabolic brain injury, traumatic brain injury, spinal cord injury, and for the alleviation of benign forgetfulness and the memory impairement in connention with dementia syndromes and neurodegenerative diseases, in a subject in need thereof, by administering to the subject an effective amount of a compound of the invention, or its pharmaceutically acceptable salt or ester either alone or in combination with another medication along with a pharmaceutically acceptable excipient. In another embodiment the invention provides methods for providing neuroprotection, for inhibiting cell degeneration or cell death, for treatment or prophylaxis of a neurodegenerative disease, or for preventingthe neurotoxic effect of a compound including, but not limited to, excitatory amino acids such as glutamate or toxins, in a subject in need thereof, by administering to the subject an effective amount of a compound of the invention, or its pharmaceutically acceptable salt or ester either alone or in combination with another medication along with a pharmaceutically acceptable excipient. In another embodiment the invention provides methods for the treatment of infections with the parasite Toxoplasma gondii in a subject in need thereof, by administering to the subject an effective amount of a compound of the invention, or its pharmaceutically acceptable salt or ester either alone or in combination with another medication along with a pharmaceutically acceptable excipient. A better understanding of the invention will be obtained from the following detailed description of the article and the desired features, properties, characteristics and the relation of the elements as well as the process steps, or with respect to each of the others, as set forth and exemplified in the description and illustrative embodiments.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GR20080100530A GR1007084B (en) | 2008-08-07 | 2008-08-07 | 1,4-benzoxazine derivatives |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GR20080100530A GR1007084B (en) | 2008-08-07 | 2008-08-07 | 1,4-benzoxazine derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
GR20080100530A GR20080100530A (en) | 2010-03-31 |
GR1007084B true GR1007084B (en) | 2010-11-26 |
Family
ID=40637180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GR20080100530A GR1007084B (en) | 2008-08-07 | 2008-08-07 | 1,4-benzoxazine derivatives |
Country Status (1)
Country | Link |
---|---|
GR (1) | GR1007084B (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1161080B (en) * | 1960-12-01 | 1964-01-09 | Geigy Ag J R | Fungicidal agent |
FR2714381B1 (en) * | 1993-12-29 | 1996-02-02 | Pharmascience Lab | Benzoxazine derivatives, processes for obtaining them and their use as medicaments. |
TW448161B (en) * | 1994-07-14 | 2001-08-01 | Otsuka Pharma Co Ltd | Cyclic amide derivatives |
-
2008
- 2008-08-07 GR GR20080100530A patent/GR1007084B/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
GR20080100530A (en) | 2010-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20084703L (en) | Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | |
TN2015000368A1 (en) | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor | |
UA110347C2 (en) | Derivative 6-cycloalkanes 1.5 dyhidropirazol [3,4-d] pyrimidine-4-one and their use as inhibitors pde9a | |
HK1116073A1 (en) | Bendamustine pharmaceutical compositions for lyophilisation | |
CA2918938C (en) | Substituted aminopyrimidine compounds and methods of use | |
MX359207B (en) | Pyrrolo[2,1-f][1,2,4]triazine compound, and preparation method and application thereof. | |
AU2012243329A8 (en) | 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors,compositions,and their use | |
EA201270824A1 (en) | COMPOUNDS TO REDUCE BET-AMYLOID PRODUCTS | |
WO2009050506A3 (en) | Combination 059 | |
WO2007002516A3 (en) | Improved dosage forms for movement disorder treatment | |
WO2017009843A3 (en) | Compositions, articles of manufacture and methods for treating cancer | |
TN2013000324A1 (en) | 6 - cyclobutyl - 1, 5 - dihydro - pyrazolo [3, 4-d] pyrimidin- 4 - one derivatives their use as pde9a inhibitors | |
MY138708A (en) | Biaryloxymethylarenecarboxylic acids | |
UA101393C2 (en) | COMPOSITIONS AND USE OF TRIAZOLE DERIVATIVES FOR TREATING β-AMYLOID DISEASES AND SYNUCLEINOPATHIES | |
UA94036C2 (en) | Bendamustine pharmaceutical compositions for lyophilisation | |
WO2014106800A3 (en) | Substituted 2-amino pyrimidine derivatives as kinase inhibitors | |
WO2011107812A3 (en) | Stabilized pharmaceutical composition | |
WO2013085849A3 (en) | Sulfate esters of noribogaine | |
WO2008135661A3 (en) | Use of citrulline for the treatment of conditions linked to an increase in protein carbonylation | |
GR1007084B (en) | 1,4-benzoxazine derivatives | |
WO2012103282A3 (en) | Methods and compositions for treating alzheimer's disease | |
CA2855719C (en) | Apoaequorin for reducing neuronal injury due to ischemia | |
WO2015107536A3 (en) | Fixed dose combination comprising linagliptin and metformin hci | |
WO2008036733A3 (en) | Methods for treatment of vesicle transport disorders | |
MX2011012717A (en) | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLI C ACID AMIDES. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PG | Patent granted | ||
ML | Lapse due to non-payment of fees |
Effective date: 20150304 |